Developer docs
API playgroundTry for free, no card

Search company profiles

ChrysCapital

Full company profile

uuid00003g1

Namestring
ChrysCapital
Legal namestring
ChrysCapital LLP
Company typeenum
Private
Founded yearint
1999
Descriptiontext

ChrysCapital is India's largest homegrown private equity firm, founded in 1999 by Ashish Dhawan and headquartered in Mumbai with fund-administration offices in Mauritius. The firm invests across six core verticals — Consumer, Enterprise Technology, Financial Services, Healthcare & Life Sciences, Manufacturing, and New Economy — through growth and control/buyout transactions. Since inception it has raised approximately $8.5 billion across ten PE funds, deployed roughly $4.5 billion into 100+ investments, and realized approximately $6.5–7 billion across 75–80 exits. The largest fund, ChrysCapital X, closed at $2.2 billion in November 2025 and is the largest India-focused PE fund ever raised.

The firm's product platform is anchored on its flagship private equity fund series, supplemented by the Clarus long-only Indian public-markets fund (launched 2023, ~$200M) and the Enhancin portfolio operations group (est. 2017), which delivers measurable value-add to portfolio companies across revenue enhancement, operational improvement, people/organization, and operational due-diligence workstreams. The firm sells institutional capital: it raises from global sovereign wealth funds, pensions, insurers, endowments, foundations, and asset managers, and—starting with Fund X—domestic Indian family offices and institutions. Deal sourcing runs through proprietary networks plus a deep bench of sector-specialist operating advisors (Sanjay Jalona ex-LTI CEO, Harsh Mariwala, Ramesh Iyer ex-Mahindra Finance, Ajay Kaul ex-Domino's India).

Revenue is generated from management fees on committed and invested capital across the fund series plus performance-based carried interest on profitable exits. The firm itself is privately held with no public ticker, and operating geographies span India (primary), US-based portfolio companies, and a global LP base. The senior investment team averages more than 20 years at ChrysCapital following a successful 2011–2012 founder transition.

Short descriptiontext

ChrysCapital is India's largest homegrown private equity firm, founded 1999, managing ~$8.5B across ten PE funds plus the Clarus long-only public-markets vehicle, investing in control and growth deals across six Indian sectors via the in-house Enhancin value-creation platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPort Louis, Mauritius
HQ citystring
Port Louis
HQ countrystring
Mauritius
HQ regionstring
Africa
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private equity investing, growth capital investment, buyout investments, portfolio value creation, fund management
Product category
Private Equity
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Private Equity Fund Management Fees
TypeSubscription Recurring
Description

Recurring management fees on committed and invested capital across ChrysCapital's PE funds (Funds I through X), generating stable annual fee income. ChrysCapital has raised $5 billion across nine PE funds and added a $2.2 billion tenth fund (Fund X), plus the long-only Clarus vehicle.

chryscapital.com
2Carried Interest / Investment Realizations
TypeOthers
Description

Performance-based carried interest on profitable exits from portfolio companies. ChrysCapital has fully exited its first six funds and realized approximately $7 billion across 80 exits (per About Us page). Recent updates cite $6.5 billion realized from 75+ exits. Notable exits include LiquidHub to CapGemini ($500M, 40% IRR/3.8x), Infogain to Apax ($900M, 42% IRR/6.5x), GeBBS Healthcare to EQT (>$800M).

chryscapital.com
3Public-Markets Investment Returns
TypeSubscription Recurring
Description

Returns from ChrysCapital's public-market investment fund deployed in BFSI and listed equities. The public-market vehicle makes concentrated bets alongside PE investments.

vccircle.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others
Pricing details3 tiers
1ChrysCapital X (Fund X) - largest ever India-focused PE fund
ModelOtherBilling cadenceMulti-year contract
Notes

Raised $2.2 billion; 60% larger than previous fund; 15% domestic Indian LP capital for the first time; deployed over 3-4 years.

chryscapital.com
2ChrysCapital IX
ModelOtherBilling cadenceMulti-year contract
Notes

Raised $1.25 billion in 2022, the largest-ever fund raised by an Indian PE firm at the time.

chryscapital.com
3Clarus (Long-Only Public Markets Fund)
ModelOtherBilling cadenceMulti-year contract
Notes

Raised approximately $200 million from Indian family offices; launched in 2023.

chryscapital.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Enhancin
Description

ChrysCapital's portfolio value creation / operations group, established in 2017, working across minority and control investments on revenue enhancement, operational improvement, people and organization, and operational due diligence.

chryscapital.com
+1 more record
Core offering1 text field

ChrysCapital is India's largest homegrown private equity firm managing a series of PE funds (most recently Fund X at $2.2 billion) that make growth and control investments in six core sectors: Consumer, Enterprise Technology, Financial Services, Healthcare & Life Sciences, Manufacturing, and New Economy. The firm also operates Clarus, a long-only public markets fund, and Enhancin, an in-house portfolio operations group that delivers revenue enhancement, operational improvement, and people/organization value-add services to portfolio companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • ~$7 billion realized across 80 exits (per About Us); updated to $6.5 billion from 75+ exits in March 2026 reporting
+5 more records
Product overview1 text field

ChrysCapital is India's largest homegrown private equity firm (founded 1999), offering a platform-plus-modules architecture of investment products and value-added services rather than a single software product. The core platform is the flagship private equity fund series (most recently ChrysCapital X at $2.2 billion), complemented by the ChrysCapital Clarus long-only public markets fund and the Enhancin portfolio operations group, which delivers value creation services to portfolio companies. The responsible investment / ESG framework is layered across all funds and sits alongside the firm's Great Place to Work certification and memberships in UN Global Compact, PRI, ESGDC, ILPA DIA, IVCA, WinPE, FICCI, US-ISPF, and PEVC CFO. Together, the ChrysCapital flagship PE funds, ChrysCapital Clarus, and Enhancin constitute an integrated investment platform targeting control and growth investments across six core sectors: Consumer, Enterprise Technology, Financial Services, Healthcare & Life Sciences, Manufacturing, and New Economy.

Product and service4 records
1ChrysCapital X (Fund X)
CategoryFlagship private equity fund
2ChrysCapital Clarus
CategoryPublic markets long-only fund
3Enhancin Portfolio Operations Group
CategoryPortfolio value creation service
4ChrysCapital Responsible Investment / ESG Framework
CategoryESG and responsible investment platform
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ICICI Venture is one of India's oldest and largest PE firms, backed by the ICICI Group, with a multi-sector India PE/VC strategy closely comparable to ChrysCapital's diversified sector approach.

2True North (India)
TypeDirect peer
Description

True North is a leading India-focused PE firm making control and minority growth investments across financial services, healthcare, consumer and technology — a direct competitor to ChrysCapital for India mid-market control deals.

TypeBroad incumbent
Description

General Atlantic operates a major growth-equity platform in India across technology, financial services and consumer — a comparable growth-investing strategy targeting many of the same sectors as ChrysCapital.

TypeBroad incumbent
Description

Advent International is a global PE firm with an active India franchise across financial services, healthcare and industrials — competing with ChrysCapital for cross-border control buyouts and growth deals in India.

TypeBroad incumbent
Description

Warburg Pincus is a long-standing global PE investor with deep India presence across financial services, consumer and technology — comparable to ChrysCapital's growth and control investment approach in India.

TypeBroad incumbent
Description

Carlyle operates a substantial India platform investing across consumer, financial services, healthcare and technology — a comparable diversified India PE strategy from a global mega-sponsor.

TypeBroad incumbent
Description

Blackstone runs the largest India-dedicated PE strategy (BCP IX) and is a leading competitor for control investments in Indian technology, financial services, and consumer — comparable in sector overlap but with materially larger AUM.

TypeBroad incumbent
Description

KKR operates a major India PE platform across buyout, growth and infrastructure, competing with ChrysCapital for large control deals and offering similar sector breadth with much larger global AUM.

TypeBroad incumbent
Description

Bain Capital has built a large India-focused PE business across consumer, financial services, healthcare and technology, directly competing with ChrysCapital for control deals in the same sectors.

TypeDirect peer
Description

Everstone is one of India's largest homegrown PE firms focused on control and growth investments across consumer, financial services, healthcare and technology — directly comparable to ChrysCapital's six-sector India PE strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment72 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ChrysCapital

Private Equitychryscapital.com

ChrysCapital is India's largest homegrown private equity firm, founded 1999, managing ~$8.5B across ten PE funds plus the Clarus long-only public-markets vehicle, investing in control and growth deals across six Indian sectors via the in-house Enhancin value-creation platform.

What ChrysCapital does

ChrysCapital is India's largest homegrown private equity firm, founded in 1999 by Ashish Dhawan and headquartered in Mumbai with fund-administration offices in Mauritius. The firm invests across six core verticals — Consumer, Enterprise Technology, Financial Services, Healthcare & Life Sciences, Manufacturing, and New Economy — through growth and control/buyout transactions. Since inception it has raised approximately $8.5 billion across ten PE funds, deployed roughly $4.5 billion into 100+ investments, and realized approximately $6.5–7 billion across 75–80 exits. The largest fund, ChrysCapital X, closed at $2.2 billion in November 2025 and is the largest India-focused PE fund ever raised.

The firm's product platform is anchored on its flagship private equity fund series, supplemented by the Clarus long-only Indian public-markets fund (launched 2023, ~$200M) and the Enhancin portfolio operations group (est. 2017), which delivers measurable value-add to portfolio companies across revenue enhancement, operational improvement, people/organization, and operational due-diligence workstreams. The firm sells institutional capital: it raises from global sovereign wealth funds, pensions, insurers, endowments, foundations, and asset managers, and—starting with Fund X—domestic Indian family offices and institutions. Deal sourcing runs through proprietary networks plus a deep bench of sector-specialist operating advisors (Sanjay Jalona ex-LTI CEO, Harsh Mariwala, Ramesh Iyer ex-Mahindra Finance, Ajay Kaul ex-Domino's India).

Revenue is generated from management fees on committed and invested capital across the fund series plus performance-based carried interest on profitable exits. The firm itself is privately held with no public ticker, and operating geographies span India (primary), US-based portfolio companies, and a global LP base. The senior investment team averages more than 20 years at ChrysCapital following a successful 2011–2012 founder transition.

ChrysCapital firmographics

Firmographics
Name
ChrysCapital
Legal name
ChrysCapital LLP
Website
https://chryscapital.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
ChrysCapital is India's largest homegrown private equity firm, founded 1999, managing ~$8.5B across ten PE funds plus the Clarus long-only public-markets vehicle, investing in control and growth deals across six Indian sectors via the in-house Enhancin value-creation platform.
Ownership category
akta.pro rank

Where ChrysCapital is headquartered

Location

Headquarters

HQ city
Port Louis
HQ country
Mauritius
HQ region
Africa

Offices3 records

Markets served

ChrysCapital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others

Revenue model

  1. Private Equity Fund Management Fees: Recurring management fees on committed and invested capital across ChrysCapital's PE funds (Funds I through X), generating stable annual fee income. ChrysCapital has raised $5 billion across nine PE funds and added a $2.2 billion tenth fund (Fund X), plus the long-only Clarus vehicle.
  2. Carried Interest / Investment Realizations: Performance-based carried interest on profitable exits from portfolio companies. ChrysCapital has fully exited its first six funds and realized approximately $7 billion across 80 exits (per About Us page). Recent updates cite $6.5 billion realized from 75+ exits. Notable exits include LiquidHub to CapGemini ($500M, 40% IRR/3.8x), Infogain to Apax ($900M, 42% IRR/6.5x), GeBBS Healthcare to EQT (>$800M).
  3. Public-Markets Investment Returns: Returns from ChrysCapital's public-market investment fund deployed in BFSI and listed equities. The public-market vehicle makes concentrated bets alongside PE investments.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractChrysCapital X (Fund X) - largest ever India-focused PE fund
OtherMulti-year contractChrysCapital IX
OtherMulti-year contractClarus (Long-Only Public Markets Fund)

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

ChrysCapital product offering

Product offering

Core offering

ChrysCapital is India's largest homegrown private equity firm managing a series of PE funds (most recently Fund X at $2.2 billion) that make growth and control investments in six core sectors: Consumer, Enterprise Technology, Financial Services, Healthcare & Life Sciences, Manufacturing, and New Economy. The firm also operates Clarus, a long-only public markets fund, and Enhancin, an in-house portfolio operations group that delivers revenue enhancement, operational improvement, and people/organization value-add services to portfolio companies.

Product overview

ChrysCapital is India's largest homegrown private equity firm (founded 1999), offering a platform-plus-modules architecture of investment products and value-added services rather than a single software product. The core platform is the flagship private equity fund series (most recently ChrysCapital X at $2.2 billion), complemented by the ChrysCapital Clarus long-only public markets fund and the Enhancin portfolio operations group, which delivers value creation services to portfolio companies. The responsible investment / ESG framework is layered across all funds and sits alongside the firm's Great Place to Work certification and memberships in UN Global Compact, PRI, ESGDC, ILPA DIA, IVCA, WinPE, FICCI, US-ISPF, and PEVC CFO. Together, the ChrysCapital flagship PE funds, ChrysCapital Clarus, and Enhancin constitute an integrated investment platform targeting control and growth investments across six core sectors: Consumer, Enterprise Technology, Financial Services, Healthcare & Life Sciences, Manufacturing, and New Economy.

Differentiator

Problem solved

Functional benefit

Brands

  • Enhancin: ChrysCapital's portfolio value creation / operations group, established in 2017, working across minority and control investments on revenue enhancement, operational improvement, people and organization, and operational due diligence.
  • Clarus

Products and services

  • ChrysCapital X (Fund X)
  • ChrysCapital Clarus
  • Enhancin Portfolio Operations Group
  • ChrysCapital Responsible Investment / ESG Framework

Quantifiable outcome

  • ~$7 billion realized across 80 exits (per About Us); updated to $6.5 billion from 75+ exits in March 2026 reporting
  • +5 more outcomes

Companies that use ChrysCapital

Customer profile

Named customers14 records

Segments6 records

Ideal customer profiles2 records

ChrysCapital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ChrysCapital partnerships and signals

Strategic signal

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

ChrysCapital competitors and assessment

Company assessment

Direct peers

  • ICICI Venture: ICICI Venture is one of India's oldest and largest PE firms, backed by the ICICI Group, with a multi-sector India PE/VC strategy closely comparable to ChrysCapital's diversified sector approach.
  • True North (India): True North is a leading India-focused PE firm making control and minority growth investments across financial services, healthcare, consumer and technology — a direct competitor to ChrysCapital for India mid-market control deals.
  • Everstone Capital: Everstone is one of India's largest homegrown PE firms focused on control and growth investments across consumer, financial services, healthcare and technology — directly comparable to ChrysCapital's six-sector India PE strategy.

Broad incumbents

  • General Atlantic (India): General Atlantic operates a major growth-equity platform in India across technology, financial services and consumer — a comparable growth-investing strategy targeting many of the same sectors as ChrysCapital.
  • Advent International (India): Advent International is a global PE firm with an active India franchise across financial services, healthcare and industrials — competing with ChrysCapital for cross-border control buyouts and growth deals in India.
  • Warburg Pincus India: Warburg Pincus is a long-standing global PE investor with deep India presence across financial services, consumer and technology — comparable to ChrysCapital's growth and control investment approach in India.
  • Carlyle India: Carlyle operates a substantial India platform investing across consumer, financial services, healthcare and technology — a comparable diversified India PE strategy from a global mega-sponsor.
  • Blackstone India: Blackstone runs the largest India-dedicated PE strategy (BCP IX) and is a leading competitor for control investments in Indian technology, financial services, and consumer — comparable in sector overlap but with materially larger AUM.
  • KKR India: KKR operates a major India PE platform across buyout, growth and infrastructure, competing with ChrysCapital for large control deals and offering similar sector breadth with much larger global AUM.
  • Bain Capital India: Bain Capital has built a large India-focused PE business across consumer, financial services, healthcare and technology, directly competing with ChrysCapital for control deals in the same sectors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

ChrysCapital social profiles

Digital presence

ChrysCapital compliance and trust

Trust signal

Compliance5 records

ChrysCapital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ChrysCapital leadership team

Management profile

Number of profiles

Profiles19 records

ChrysCapital subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

ChrysCapital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ChrysCapital M&A and investment

M&A and investment

M&A6 records

Investments72 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ChrysCapital

What does ChrysCapital do?

ChrysCapital is India's largest homegrown private equity firm managing a series of PE funds (most recently Fund X at $2.2 billion) that make growth and control investments in six core sectors: Consumer, Enterprise Technology, Financial Services, Healthcare & Life Sciences, Manufacturing, and New Economy. The firm also operates Clarus, a long-only public markets fund, and Enhancin, an in-house portfolio operations group that delivers revenue enhancement, operational improvement, and people/organization value-add services to portfolio companies.

Is ChrysCapital a public or private company?

ChrysCapital is a private company. It is classified as management employee owned and is currently operating.

When was ChrysCapital founded?

ChrysCapital was founded in 1999. It employs 11 to 50 people.

Where is ChrysCapital based?

ChrysCapital is headquartered in Port Louis, Mauritius, in the Africa region.

How does ChrysCapital make money?

Three revenue lines are on record. Private Equity Fund Management Fees are the primary driver. The others are carried Interest / Investment Realizations and public-Markets Investment Returns.

Who are ChrysCapital's main competitors?

Direct peers on record are ICICI Venture, True North (India) and Everstone Capital. Broad incumbents are General Atlantic (India), Advent International (India), Warburg Pincus India, Carlyle India, Blackstone India, KKR India and Bain Capital India.

Does ChrysCapital have an API?

No public API is recorded for ChrysCapital.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business News TodayNuvama stake sale to see binding bids soon; EQT & ChrysCapital in lead as Brookfield drops out- Moneycontrol.comPAG's sale of its 53.40% stake in Nuvama Wealth Management is expected to receive binding bids in November, with EQT and ChrysCapital as lead suitors after Brookfield dropped out. The stake is valued at about Rs 18,379 crore, making it one of India's largest financial services deals.The KenNovartis India’s headcount: 57. Chryscapital’s price for it: Rs 1,400 cr. Investors after the deal: “We love it”Chryscapital acquired 70.68% of Novartis India for Rs 1,400 crore, renaming it Evonile Pharma. The company now plans a Rs 885 crore rights issue to repay debt from buying Pfizer's Minipress XL. The stock trades at about 60 times EV/Ebitda, twice that of Mankind Pharma.TradingViewPlatform deals on the rise in pharma and healthcare: Rothschild & Co. MD Subhakanta BalRothschild & Co. MD Subhakanta Bal said private equity and strategic buyers are increasingly building scaled pharma and healthcare businesses through acquisitions. KKR agreed to buy Medicover's India hospital business for about $1.4 billion, and ChrysCapital acquired a 70.68% stake in Novartis India. He expects continued consolidation in domestic branded formulations and healthcare services.WhalesbookIndian Pharma and Healthcare See Wave of Buy-and-Build M&AIndian pharma and healthcare firms are adopting buy-and-build M&A to consolidate fragmented markets, with private equity firms like KKR and ChrysCapital leading. Domestic players such as Torrent and Mankind are also acquiring local assets, while firms target outbound growth in Europe and emerging markets. Investors should monitor integration risks and debt pressures from these deals.MintPlatform deals on the rise in pharma and healthcare: Rothschild & Co. MD Subhakanta Bal | MintPrivate equity and strategic buyers are increasingly pursuing platform deals in India's pharma and healthcare sectors, aiming for scale and efficiency. Examples include ChrysCapital's stake in Novartis India and KKR's $1.4 billion acquisition of Medicover's India hospital business. The trend is expected to drive more domestic and outbound M&A.The Times of IndiaGeneral Atlantic, ChrysCapital in talks to invest Rs 300-400 crore in ice cream brand Hocco; valuation may jump 80% - The Economic TimesGeneral Atlantic and ChrysCapital are in talks to invest Rs 300-400 crore in Hocco Ice Cream, a D2C brand. The round would value the Ahmedabad-based company at Rs 4,000-4,500 crore, an 80% increase from its last valuation of Rs 2,500 crore.Indian Startup NewsChrysCapital, Tata Capital Healthcare Fund invest $70 million in Chennai-based Linux LaboratoriesChennai-based Linux Laboratories raised $70 million in equity from ChrysCapital and Tata Capital Healthcare Fund III, with ChrysCapital taking a significant minority stake and Tata Capital exiting TCHF II with about 4x returns. The funds will support expansion into new therapeutic areas, brand acquisitions, and manufacturing and R&D investments.The Times of IndiaChrysCapital to take minority stake in Linux laboratoriesChrysCapital and Tata Capital Healthcare Fund III provided $70 million in equity funding to Linux Laboratories, with ChrysCapital taking a minority stake. The deal includes a secondary purchase and Tata Capital's full exit. Proceeds will support brand acquisitions and R&D investment.YourStoryLinux Laboratories raises $70M from ChrysCapital and Tata Capital Healthcare FundLinux Laboratories raised $70 million in equity from ChrysCapital and Tata Capital Healthcare Fund III, with ChrysCapital taking a minority stake and Tata Capital Healthcare Fund II exiting at about 4x returns. The company will use the funds to expand in core specialties, enter adjacent therapeutic areas, and invest in manufacturing and R&D.Business News TodayLinux Laboratories raises $70 million from ChrysCapital, Tata Capital Healthcare Fund- Moneycontrol.comLinux Laboratories raised $70 million in equity from ChrysCapital and Tata Capital Healthcare Fund III. The funds will support expansion into adjacent therapeutic areas, brand acquisitions, and manufacturing and R&D investments.